Early studies of metformin in NASH showed significant reduction in hepatic steatosis and ALT, but histologic follow-up data are scarce and have not shown improvement in hepatic necroinflammatory grades [101–103], except in one study where it correlated with the degree of weight loss [101]. This evidence concerns the gene GPT and fatty liver disease.